Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q3 2024

Cerevel Therapeutics reports successful 2022, eyes transformative neuroscience advancements

Cerevel Therapeutics had a productive year, focusing on transformative neuroscience.
Strong financial position with cash resources to fund operations into 2025.
Facing challenges with trial delays but addressing them with mitigation plans.
Opportunities lie in upcoming data readouts and exploring new indications.

Cerevel Therapeutics reports strong financials, navigates trial challenges for growth

Cerevel Therapeutics is well-positioned financially with a focus on operational efficiency and trial success, supported by strong cash reserves.
The company faces challenges in pipeline management and trial enrollment dynamics, necessitating strategic adjustments and careful oversight.
Opportunities lie in external growth initiatives, potential product approvals, and expanding therapeutic reach through strategic trial designs.

Cerevel Therapeutics advances key programs amidst challenges, eyes growth opportunities

Cerevel Therapeutics is making progress in key programs, leveraging its strong balance sheet and commitment to patients. Challenges in trial delays and patient selection criteria persist, but the company's focus on quality data and financial strength bode well for future growth.

Cerevel Therapeutics excels in Q3 with robust pipeline and financials

Cerevel Therapeutics demonstrated robust performance in Q3 2023, driven by a strong pipeline and solid financial foundation.
While facing challenges like high rollover rates and data disclosure timelines, the company is well-positioned to capitalize on transformative opportunities.
Strategic focus on quality, innovation, and market expansion underscores Cerevel's commitment to advancing novel therapies for neurological disorders.
With key data readouts expected in 2024 and a clear roadmap for regulatory filings, Cerevel is poised for significant growth and impact in the neurology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Positive topline results from the company's schizophrenia candidate were better than expected.

Here's Why Cerevel Therapeutics Stock Is Shooting Through the Roof Today

The stock price of Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) increased by over 60% pre-market. This is why it happened.

CERE Stock Price Increases Over 60% Pre-Market: Why It Happened

Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo

Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia

CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy.

Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in two upcoming virtual investor conferences during the month of June.

Cerevel Therapeutics to Present at Upcoming Virtual Investor Conferences

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q1 2021 Results - Earnings Call Transcript

Announced strategic $125 million non-dilutive financing for tavapadon

Cerevel Therapeutics Reports First Quarter 2021 Financial Results and Business Updates

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2021 financial results on Monday, May 17, 2021, before the U.S. financial markets open.

Cerevel Therapeutics to Report First Quarter 2021 Financial Results on Monday, May 17, 2021

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Abraham N. Ceesay to the newly-created role of president, effective May 3, 2021. Mr. Ceesay brings nearly two decades of healthcare experience leading operations at a number of biopharmaceutical companies, serving most recently as chief executive officer at Tiburio Therapeutics, a privately-held biotechnology company. As president, he will be responsible for developing Cerevel's commercial capabilities and infrastructure and will oversee corporate strategy, business development, and portfolio and program management.

Cerevel Therapeutics Appoints Abraham N. Ceesay as President

The stock price of Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) increased by over 9% pre-market. This is why it happened.

CERE Stock: Over 9% Increase Pre-Market Explanation

Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinson's disease through planned NDA submission

Cerevel Therapeutics Announces Strategic $125 Million Non-Dilutive Financing Transaction for Tavapadon

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q4 2020 Results - Earnings Call Transcript

Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021

Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2020 Financial Results

CAMBRIDGE, Mass., March 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 3rd Annual CNS Day on Wednesday, March 31, 2021 at 9:00 a.m. EDT.

Cerevel Therapeutics to Present at the Stifel 3rd Annual CNS Day Event

Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator

Cerevel Therapeutics Hosts Inaugural Virtual R&D Event to Review Darigabat (CVL-865) and Provide Overview of Key Preclinical Programs

Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs

Cerevel Therapeutics to Host Inaugural Virtual R&D Event

CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Ruth McKernan, Ph.D., CBE, FMedSci, to serve as an independent member of its Board of Directors. Dr. McKernan currently serves as a venture partner with SV Health Investors, LLP, a global investment firm and specialist healthcare fund manager, where she supports companies that create new medicines for treating neurodegenerative disorders. With over 25 years of academic, research and commercial experience in the pharmaceutical industry, Dr. McKernan also serves as chairperson of the BioIndustry Association, a trade association for innovative life sciences in the United Kingdom, and as a trustee of Alzheimer's Research UK, the country's leading dementia research charity.

Cerevel Therapeutics Announces the Appointment of Dr. Ruth McKernan to its Board of Directors

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a live webcast providing a current corporate overview, followed by a moderated question and answer session on Monday, December 14.  

News for Cerevel Therapeutics Holdings Inc Stock (CERE)